ONO 7269
Alternative Names: ONO-7269Latest Information Update: 19 Jan 2022
At a glance
- Originator Ono Pharmaceutical
- Class Anti-ischaemics; Anticoagulants; Vascular disorder therapies
- Mechanism of Action Factor XIa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cerebral infarction
Most Recent Events
- 19 Jan 2022 Discontinued - Phase-I for Cerebral infarction (In volunteers) in Japan (IV) (Ono Pharmaceuticals pipeline, January 2022)
- 28 Oct 2021 No recent reports of development identified for phase-I development in Cerebral-infarction(In volunteers) in Japan (IV, Infusion)
- 01 Sep 2018 Phase-I clinical trials in Cerebral infarction (In volunteers) in Japan (IV) (JapicCTI184173)